Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Alice TisonGilles QuéréLaurent MiseryElisa Funck-BrentanoFrançois-Xavier DanlosEmilie RoutierCaroline RobertYohann LoriotOlivier LambotteBertille BonniaudCamille ScalbertSarah MaanaouiThierry LesimpleStéphanie MartinezMarie MarcqChristos ChouaidCatherine DubosFlorence Brunet-PossentiChloé StavrisLaurent ChicheNathalie BenetonSandrine MansardFlorian GuisierHélène DoubreFrançois SkowronFrançois AubinOuidad ZehouChristophe RogeMickaël LambertAnne Pham-LedardMarie Beylot-BarryRémi VeillonNora KramkimelDamien GiaccheroJulie De QuatrebarbesCatherine MichelJean-Bernard AuliacGilles GonzalesChantal DecroisetteGwenaelle Le GarffIoana CarpiucHervé VallerandEmmanuel NowakDivi CornecMarie Kostinenull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
Our findings indicate that flares or IRAEs occur frequently but are mostly manageable without ICI discontinuation in patients with a preexisting autoimmune disease. Immunosuppressive therapy at baseline is associated with poorer outcomes.